China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has priced its offering of 11,910,286 global depository receipts (GDRs) to the SWX Swiss Exchange (SWX) at USD 12.31 to USD 12.68 per share. The proceeds from the offering are expected to range from USD 148.8 million to as much as USD 221 million. These funds will be used to develop the firm’s international activities, marking a significant step in its global expansion strategy.
Company Profile and Core Products
Founded in 1999, Lepu Medtech is a leading provider of cardiovascular disease solutions, offering a comprehensive range of medical devices, drugs, and healthcare solutions. The company’s core products include the coronary drug-eluting stent, coronary bioabsorbable stent, coronary drug-coated balloon, congenital heart disease occluder, and coronary cutting balloon. These products have established Lepu Medtech as a key player in the cardiovascular medical device market.
Strong Financial Performance
Lepu Medtech made its debut on the Shenzhen Stock Exchange in October 2009 and has since recorded impressive financial performance. Over the past 15 years, the company has achieved a compound annual growth rate of 31.5% in revenues and 24.9% in net profits. This strong track record underscores Lepu Medtech’s ability to innovate and deliver value in the cardiovascular healthcare sector.-Fineline Info & Tech
